Takeda’s lung cancer drug approved in the US
Pharma times | May 02, 2017
The US Food and Drug Administration has given permission for the once-daily drug’s use as a second-line therapy for adults with non-small cell lung cancer (NSCLC) who also carry the anaplastic lymphoma kinase (ALK) mutation.